Johnson & Johnson (JNJ)vsLiquidia Technologies Inc (LQDA)
JNJ
Johnson & Johnson
$276.25
+1.43%
HEALTHCARE · Cap: $657.68B
LQDA
Liquidia Technologies Inc
$44.40
-0.20%
HEALTHCARE · Cap: $4.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 21930% more annual revenue ($99.33B vs $450.91M). LQDA leads profitability with a 30.7% profit margin vs 16.2%. LQDA trades at a lower P/E of 32.4x. LQDA earns a higher WallStSmart Score of 60/100 (C).
JNJ
Buy54
out of 100
Grade: C-
LQDA
Buy60
out of 100
Grade: C
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 49.8%
Revenue surging 1843.0% year-over-year
Every $100 of equity generates 28 in profit
Areas to Watch
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
0.0% earnings growth
Trading at 20.3x book value
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : LQDA
The strongest argument for LQDA centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 30.7% and operating margin at 49.8%. Revenue growth of 1843.0% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : LQDA
The primary concerns for LQDA are P/E Ratio, EPS Growth, Price/Book.
Key Dynamics to Monitor
JNJ profiles as a mature stock while LQDA is a growth play — different risk/reward profiles.
LQDA carries more volatility with a beta of 0.61 — expect wider price swings.
LQDA is growing revenue faster at 1843.0% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
LQDA scores higher overall (60/100 vs 54/100), backed by strong 30.7% margins and 1843.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?